San Francisco, CA – According to filings with the U.S. Securities and Exchange Commission, Aeovian Pharmaceuticals has raised $37 Million in Series A financing. Sources indicate as part of senior management Chief Executive Officer, Stelios Tzannis played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Aeovian Pharmaceuticals

At Aeovian Pharmaceuticals we are a San Francisco Bay Area-based research stage biopharmaceutical company aiming to discover, develop and commercialize innovative therapeutics for the treatment of rare and age-related diseases.  We are developing compounds to modulate molecular pathways that address the underlying causes of disease initiation and progression, such as oxidative, cellular and environmental stress.

To learn more about Aeovian Pharmaceuticals, visit http://www.aeovian.com/

Contact:
Stelios Tzannis, Chief Executive Officer
415-209-2055
https://www.linkedin.com/in/tzannis/

SOURCE: http://www.intelligence360.io
Copyright (c) 2019 SI360 Inc. All rights reserved